We found that BMMC injection increased the expression of CCL17 and CCL22 in tumor microenvironment, evaluated by real time RT-PCR (Fig. 4B), which could be blunted by IL-17 neutralization or blocking MDSC migration (Fig. 4B). This evidence concerns the gene CCL22 and neoplasm.